OKYO Pharma to Present First-in-Human Urcosimod Phase 1 Results at ARVO 2026
OKYO Pharma will present first-in-human clinical data for its lead candidate urcosimod at the ARVO 2026 annual meeting. The presentation will cover safety, tolerability and pharmacokinetic results from its initial Phase 1 trial in healthy volunteers.
1. Presentation Schedule and Details
OKYO Pharma is slated to present its initial human trial findings for urcosimod at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in 2026. The session will outline the design of the Phase 1 study, key endpoints and patient cohort characteristics.
2. Urcosimod Phase 1 Data Focus
The Phase 1 trial evaluated single- and multiple-ascending doses of urcosimod in healthy volunteers to assess safety, tolerability and pharmacokinetics. Early results will detail adverse event profiles, dose-dependent exposure levels and preliminary biomarker responses.
3. Strategic Implications for OKYO
Positive safety and pharmacokinetic data could de-risk urcosimod’s development path and accelerate planning for patient-based studies. Successful Phase 1 outcomes may enhance investor confidence and clarify timing for a Phase 2 trial in target ocular indications.